<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343511</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-AUTISM-1.0(2009)</org_study_id>
    <nct_id>NCT01343511</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Stem Cell Therapy in Patients With Autism</brief_title>
  <official_title>Phase Ι/Π Study of Stem Cell Therapy in Patients With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Jiaotong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association for the Handicapped Of Jinan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by&#xD;
      social interaction abnormalities, impaired verbal and non-verbal communication, and&#xD;
      repetitive, obsessive behavior, while the therapeutic effect of current treatments remains&#xD;
      limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies&#xD;
      associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord&#xD;
      blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune&#xD;
      response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy.&#xD;
      In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be&#xD;
      evaluated in patients with Autism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of human cord blood mononuclear cells and human&#xD;
      umbilical cord mesenchymal stem cells transplantation in patients of Autism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Childhood Autism Rating Scale，CARS</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression Scale，CGI</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist，ABC</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event and Serious Adverse Event</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Rehabilitation plus hCB-MNCs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rehabilitation plus hCB-MNCs and hUC-MSCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells</intervention_name>
    <description>Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.</description>
    <arm_group_label>Rehabilitation plus hCB-MNCs treatment</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.</description>
    <arm_group_label>Rehabilitation plus hCB-MNCs and hUC-MSCs therapy</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children between the ages of 3 and 12 years.&#xD;
&#xD;
          -  DSM-IV diagnosis of Autistic Disorder.&#xD;
&#xD;
          -  Total score of CARS ≥ 30.&#xD;
&#xD;
          -  Parents or legal guardian willing to sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of hypersensitivity to serum products, or other known drug and food&#xD;
             allergy.&#xD;
&#xD;
          -  History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar&#xD;
             disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified&#xD;
             (PDD NOS), Asperger's, or Rett's.&#xD;
&#xD;
          -  History of Epileptic seizure activity in the past 6 months.&#xD;
&#xD;
          -  Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.&#xD;
&#xD;
          -  The global autism ratings are assessed as being absent, minimal or mild.&#xD;
&#xD;
          -  Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive&#xD;
             dyskinesia.&#xD;
&#xD;
          -  Subjects who have displayed significant self-injurious behavior (children who have&#xD;
             caused visible harm to themselves).&#xD;
&#xD;
          -  HIV+&#xD;
&#xD;
          -  Acute and chronic hepatitis.&#xD;
&#xD;
          -  Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.&#xD;
&#xD;
          -  Severe pulmonary and hematological disease, malignancy or hypo-immunity.&#xD;
&#xD;
          -  Currently undertaking other treatment that may affect the safety/efficacy of stem&#xD;
             cells.&#xD;
&#xD;
          -  Enrollment in other trials in the last 3 months.&#xD;
&#xD;
          -  Other criteria the investigator consider improper for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongtao Lv</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Jiaotong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandong Jiaotong Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Liu M, Sun LW, LV YT, Huan Y, Ge RC, Cao YL, Guo CQ, Chen XW. Stem cells for treatment of autism: Safety and efficacy. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(32): 5967-5970.</citation>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>human cord blood mononuclear cells</keyword>
  <keyword>human umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

